gms | German Medical Science

55. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e. V. (DGNC)
1. Joint Meeting mit der Ungarischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

25. bis 28.04.2004, Köln

Controlled release of mitoxantrone from Ethylene-vinyl acetate copolymer for intracerebral drug delivery

Kontrollierte Freisetzung von Mitoxantron aus Etylen-vinyl-Acetat Bioploymeren für intrazerebrale Medikamentenapplikation

Meeting Abstract

  • corresponding author Florian Roser - Neurochirurgische Klinik, Klinikum Hannover Nordstadt, Hannover
  • M. Saini - Neurochirurgische Klinik, Klinikum Hannover Nordstadt, Hannover
  • C. Matthies - Neurochirurgische Klinik, Klinikum Hannover Nordstadt, Hannover
  • M. Bellinzona - Neurochirurgische Klinik, Klinikum Hannover Nordstadt, Hannover

Deutsche Gesellschaft für Neurochirurgie. Ungarische Gesellschaft für Neurochirurgie. 55. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), 1. Joint Meeting mit der Ungarischen Gesellschaft für Neurochirurgie. Köln, 25.-28.04.2004. Düsseldorf, Köln: German Medical Science; 2004. DocP 06.62

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/dgnc2004/04dgnc0345.shtml

Published: April 23, 2004

© 2004 Roser et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Objective

Mitoxantrone has demonstrated a broad anti-tumoural spectrum in a number of clinical trials as single agent and in combination chemotherapy. However, systemic administration does not reach therapeutical concentration in the brain. In this study we coupled an ethylene-vinyl-acetate copolymer with mitoxantrone to test in vitro and in vivo effects.

Methods

In vitro mitoxantrone was released from the polymeric matrix in a controlled, tapering fashion at a decreasing rate for 30 days. For in vivo studies, rats had mitoxantrone polymers implanted in the brain (i.c.), intraperitoneally (i.p.) or received mitoxantrone injections i.p.. Blood plasma levels of mitoxantrone and leucocyte count were obtained at different time points. Rats were sacrificed at the appearance of irreversible systemic and neurological deterioration and autopsy was performed.

Results

All the rats that were treated with intraperitoneal mitoxantrone injections showed progressive deterioration and died within 8 days after implant. At autopsy, no pathological changes were detected in the extracerebral organs of all animals treated with EVAc implants of mitoxantrone.

Conclusions

The intracerebral implantation of the compound can achieve high levels of mitoxantrone in the brain and reduce systemic toxicity. Controlled intracerebral biopolymer-mediated delivery of mitoxantrone may be of value in the treatment of brain tumors.